Trial Profile
A Phase IV, Multisite Study of the Treatment of Chronic Hepatitis C Virus Infection Genotype 1 in a Real World Large Health Maintenance Organization: An Evaluation of Real World Sustained Virological Response and Patient Reported Outcomes
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Jan 2021
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 21 Jan 2021 Status changed from active, no longer recruiting to completed.
- 03 May 2018 Planned End Date changed from 1 Jun 2017 to 1 Jul 2018.
- 18 Oct 2016 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017.